Usefulness of a co-registration strategy with iFR in long and/or diffuse coronary lesions (iLARDI): study protocol

• Published in: REC, Interventional cardiology (Internet. English ed.) Vol. 3; no. 3; pp. 190 - 195
• Main Authors: Hidalgo, Francisco, Ojeda, Soledad, de Lezo, Javier Suárez, Romero, Miguel, Lostalo, Adrián, González, Rafael, Pericet, Cristina, Paredes, Nick, C. Elizalde, Juan, Luque, Aurora, Mazuelos, Francisco, Segura, José, Pan, Manuel
• Format: Journal Article
• Language: English
• Published: Permanyer 01-07-2021
• Subjects: Diffuse coronary artery disease; Instantaneous wave-free ratio; Long coronary artery disease; SyncVision software
• ISSN: 2604-7322; 2604-7322
• DOI: 10.24875/RECICE.M20000143

ABSTRACT Introduction and objectives: patients with long, sequential and diffuse coronary lesions who undergo a percutaneous coronary intervention remain at a high risk of suffering cardiovascular events despite the improved safety and efficacy of the new drug-eluting stents. The objective of this study was to analyze the utility of SyncVision/iFR-guided revascularization (SyncVision version 4.1.0.5, Philips Volcano, Belgium) in this type of lesions. Methods: Randomized, multicenter, controlled, and open-label trial designed to compare SyncVision/iFR-guided and angiography-guided revascularizations in patients with long, sequential or diffuse significant angiographic coronary stenosis (ClinicalTrials.gov identifier: NCT04283734). A total of 100 patients will be randomized (1:1, no stratification). The primary endpoint is the average length of the stent implanted. The secondary endpoint is a composite of cardiac death, myocardial infarction, definitive or probable stent thrombosis, new target lesion revascularization or new target lesion failure; and the presence of residual ischemia as seen on single-photon emission computed tomography at the 6-month follow-up. Patients will be followed for 12 months after the procedure. Results: The trial is currently in the recruitment phase, and it has already recruited the first 7 patients. We expect to complete the recruitment phase by February 2021 and the follow-up by February 2022. Conclusions: The iLARDI study is the first randomized trial to assess the potential utility of SyncVision-guided revascularization in long, sequential and diffuse coronary lesions.